A REVIEW ON THE ROLE OF ASROCYTE ELEVATED GENE-1 IN CANCER

AEG-1 expression is known to elevate in diverse cancers, where it plays a primary role in activating multiple signaling pathways that drives copious oncogenic properties. The versatile role of AEG-1 in mediating oncogenesis was found to be cognate with numerous signaling cascades such as the activation of NF-κB/p65, Ha‑Ras, PI3K/Akt, ERK/MAPK, Wnt/β-catenin, AURKA and RNAi pathways. In addition, recent clinical studies reveal that AEG-1 interaction with SND1/AGO2 in RISC may stimulate oncogenic transformation. The defeat of AEG-1 leads to PARP cleavage catalyzed by caspase-3, a key process in mediating apoptosis in AEG-1 expressed cancer cells. Moreover, AEG-1 confers chemo-résistance of cancer cells by inducing autophagy. In recent past, there are several studies reveal that AEG-1 down regulation inhibits chemo-resistance and oncogenic properties of various cancers. With this background, this review will address the multifaceted role of AEG-1 as oncogene and stipulating its potential to become a new therapeutic target and prognostic biomarker for the treatment of cancer.